Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
This pharmacokinetic profile allows for once-weekly dosing, distinguishing it from shorter-acting GLP-1 compounds
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
These medications, including semaglutide and liraglutide, work by enhancing insulin secretion while also promoting weight loss
The extent to which these changes reflect GLP-1R pharmacologically mediated events versus changes that are secondary to weight loss remains unclear
Other semaglutide rare risks include cardiovascular events and changes in mood, such as depression
